About Ypsomed Holding AG

Company Description

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands, mylife Diabetescare directly to patients or through pharmacies and clinics, and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies.

Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors.

Year founded

2003

Served area

Worldwide

Headcount

1,800

Headquarters

Brunnmattstrasse 6, 3401 Burgdorf – Switzerland

Shareholder information

Shares outstanding

12,633,244

IPO

Sept. 22, 2004

Stock exchange(s)

SIX Swiss Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.